| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.051 | 0.5 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.5 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.036 | 0.5 |